文献速递心脑血管急症消化、代谢与肾脏急症

急性心肌梗死PCI术前启用依洛尤单抗降低LDL胆固醇:AMUNDSEN随机临床试验

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-08-29
一句话结论急性心梗PCI患者一线使用依洛尤单抗可快速持续降LDL-C,1年达标率82% vs 40%,但1年内未观察到临床获益。

AMUNDSEN为国际、4期、前瞻性随机、开放标签、盲法终点裁决研究,纳入48个中心、6个国家的高危急性心梗行PCI患者2161例(平均67岁,79%男性,58% STEMI)。患者1:1随机接受依洛尤单抗140 mg皮下注射每2周1年(首次注射在PCI前)联合标准治疗(n=1087)或单纯标准治疗(n=1074)。主要终点为12个月LDL-C<55 mg/dL且较基线降低≥50%,依洛尤单抗组82% vs 标准治疗组40%(校正OR 5.54,95%CI 4.50-6.82,P<.001);6周中位LDL-C为16 mg/dL vs 56 mg/dL。主要临床终点全因死亡或非计划心血管住院12个月为14.6% vs 15.4%(校正OR 0.94,95%CI 0.73-1.19,P=.59)。结论:一线依洛尤单抗降脂快速达标,但1年内未检测到临床获益。

要点

  • 高危急性心梗行PCI患者,PCI术前启用依洛尤单抗140 mg皮下每2周1年,12个月LDL-C<55 mg/dL且降幅≥50%达标率82% vs 标准治疗40%(校正OR 5.54,95%CI 4.50-6.82)。
  • 6周中位LDL-C:依洛尤单抗组16 mg/dL vs 标准治疗组56 mg/dL,提示降脂作用快速。
  • 12个月全因死亡或非计划心血管住院:依洛尤单抗组14.6% vs 标准治疗组15.4%(校正OR 0.94,95%CI 0.73-1.19,P=.59),未检测到临床获益。
  • 对照组标准治疗包括高强度口服降脂治疗,可按指南适应证选用PCSK9抑制剂。
  • 研究结论不支持在标准治疗基础上、为急性多效性作用而在PCI围术期常规启用PCSK9抑制剂。

适用人群与场景

  • 高危急性心梗行PCI的成人:年龄>55岁的STEMI患者,或具有1项及以上额外高危特征的NSTEMI患者。
  • 研究在48个中心、6个国家开展,纳入2161例随机患者(平均67岁,79%男性,58% STEMI,42% NSTEMI)。

诊断标准与关键阈值

  • 主要疗效终点达标标准:12个月时LDL-C<55 mg/dL且较基线降低≥50%。
  • 主要临床终点:12个月全因死亡或非计划心血管住院。

处置流程与药物剂量

  • 第一步:高危急性心梗行PCI患者随机分组。
  • 第二步:依洛尤单抗组在PCI前首次皮下注射依洛尤单抗140 mg,此后每2周1次,持续1年,并联合标准治疗。
  • 第三步:标准治疗包括高强度口服降脂治疗;对照组可按指南适应证选用PCSK9抑制剂。
  • 目标值:12个月LDL-C<55 mg/dL且较基线降低≥50%。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:国际、4期、前瞻性随机、开放标签、盲法终点裁决研究;48个中心、6个国家;2161例高危急性心梗行PCI患者。
  • 干预与对照:依洛尤单抗140 mg皮下每2周1年(首次PCI前)联合标准治疗(n=1087)vs 单纯标准治疗(n=1074)。
  • 主要终点:12个月LDL-C<55 mg/dL且较基线降低≥50%,依洛尤单抗组82%(792/970)vs 标准治疗组40%(370/934),校正OR 5.54(95%CI 4.50-6.82),P<.001。
  • 6周中位LDL-C:依洛尤单抗组16 mg/dL vs 标准治疗组56 mg/dL。
  • 主要临床终点:12个月全因死亡或非计划心血管住院,依洛尤单抗组14.6%(159/1087)vs 标准治疗组15.4%(165/1074),校正OR 0.94(95%CI 0.73-1.19),P=.59。

证据类型、等级与局限

  • 证据类型:随机对照试验(4期、开放标签、盲法终点裁决)。
  • 局限:开放标签设计;随访仅1年,未能评估长期临床获益;主要终点为替代指标(LDL-C达标)。

对床旁实践的改变

  • 支持对高危急性心梗行PCI患者,在PCI术前即启用依洛尤单抗联合高强度口服降脂,以快速达到LDL-C<55 mg/dL且降幅≥50%的目标。
  • 不应期望在标准治疗基础上、PCI围术期启用PCSK9抑制剂能在1年内带来全因死亡或非计划心血管住院的额外获益。
  • 对照组可按指南适应证使用PCSK9抑制剂,因此本研究比较的是「一线常规启用」与「按指南备用」策略,而非完全排除PCSK9抑制剂。

指南或共识出处

  • 原文未提及指南或共识名称;研究注册号:ClinicalTrials.gov NCT04951856。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition is recommended as second- or third-line lipid-lowering therapy after myocardial infarction (MI), resulting in prolonged periods of inadequate low-density lipoprotein cholesterol (LDL-C) control. Whether in-catheterization laboratory decision of PCSK9 inhibition, started before mechanical reperfusion, could improve LDL-C control and clinical outcomes at 1 year is unknown.

OBJECTIVE: To evaluate evolocumab as first-line therapy vs standard care in patients with high-risk acute MI undergoing percutaneous coronary intervention (PCI).

DESIGN, SETTING, AND PARTICIPANTS: This international, phase 4, prospective randomized, open, blinded end-point adjudication study was conducted at 48 sites in 6 countries. Adults with high-risk ST-elevation MI (STEMI; aged >55 years) or non-ST-elevation MI (NSTEMI) with 1 or more additional high-risk characteristics were enrolled beginning September 29, 2021, through May 22, 2025, with final follow-up on May 22, 2026.

INTERVENTIONS: Patients were randomized 1:1 to receive evolocumab 140 mg subcutaneously every 2 weeks for 1 year (first injection before PCI) in addition to standard care (n = 1087) or standard care alone (n = 1074). Standard care included high-intensity oral lipid-lowering therapy with the optional PCSK9 inhibitor use per guideline indication in the control group.

MAIN OUTCOMES AND MEASURES: The primary outcome was LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months. The main clinical end point was all-cause death or unplanned cardiovascular hospitalization at 12 months.

RESULTS: Among 2161 randomized patients (mean age, 67 years; 1703 males [79%]; 1261 [58%] with STEMI; 900 [42%] with NSTEMI), the primary outcome was achieved in 792 of 970 patients (82%) with evolocumab vs 370 of 934 (40%) with standard care (adjusted odds ratio, 5.54 [95% CI, 4.50-6.82]; P < .001). At 6 weeks, median LDL-C was 16 mg/dL with evolocumab vs 56 mg/dL with standard care. The main clinical end point occurred in 159 of 1087 patients (14.6%) with evolocumab vs 165 of 1074 (15.4%) with standard care (adjusted odds ratio, 0.94 [95% CI, 0.73-1.19]; P = .59).

CONCLUSIONS AND RELEVANCE: In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year. However, no clinical benefit was detected during the first year of follow-up, arguing against clinically meaningful acute pleiotropic effects of PCSK9 inhibitors in addition to standard care.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04951856.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Montalescot G, Ferrari E, Souteyrand G, et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026. PMID: 42666092. doi:10.1001/jama.2026.17302

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。